TRACON PHARMACEUTICALS INC's ticker is TCON and the CUSIP is 89237H209. A total of 27 filers reported holding TRACON PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $110,314 | -49.0% | 619,740 | -16.6% | 0.00% | – |
| Q2 2023 | $216,238 | -80.6% | 743,088 | +25.7% | 0.00% | – |
| Q1 2023 | $1,117,028 | +26.8% | 591,020 | 0.0% | 0.00% | – |
| Q4 2022 | $880,619 | -10.7% | 591,020 | +0.1% | 0.00% | – |
| Q3 2022 | $986,000 | -16.5% | 590,688 | 0.0% | 0.00% | – |
| Q2 2022 | $1,181,000 | -24.0% | 590,688 | 0.0% | 0.00% | – |
| Q1 2022 | $1,554,000 | -18.8% | 590,688 | -14.5% | 0.00% | – |
| Q4 2021 | $1,913,000 | -28.9% | 690,622 | -0.6% | 0.00% | – |
| Q3 2021 | $2,689,000 | -39.9% | 694,859 | +0.8% | 0.00% | – |
| Q2 2021 | $4,472,000 | -21.6% | 689,038 | -0.6% | 0.00% | – |
| Q1 2021 | $5,705,000 | +56.6% | 693,216 | +122.7% | 0.00% | – |
| Q4 2020 | $3,643,000 | +4757.3% | 311,341 | +2040.4% | 0.00% | – |
| Q3 2020 | $75,000 | +158.6% | 14,546 | 0.0% | 0.00% | – |
| Q2 2020 | $29,000 | +16.0% | 14,546 | 0.0% | 0.00% | – |
| Q1 2020 | $25,000 | -26.5% | 14,546 | 0.0% | 0.00% | – |
| Q4 2019 | $34,000 | – | 14,546 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 4,764,508 | $9,004,920 | 2.70% |
| Ikarian Capital, LLC | 2,765,530 | $5,226,851 | 1.19% |
| JOHNSON & JOHNSON | 84,003 | $158,766 | 0.05% |
| X-Square Capital, LLC | 17,743 | $34 | 0.02% |
| BOOTHBAY FUND MANAGEMENT, LLC | 258,844 | $489,215 | 0.01% |
| LINDEN ADVISORS LP | 454,916 | $859,791 | 0.01% |
| HoyleCohen, LLC | 13,000 | $24,570 | 0.00% |
| MGO ONE SEVEN LLC | 11,780 | $22,264 | 0.00% |
| Bank of New York Mellon Corp | 66,606 | $125,885 | 0.00% |
| Citadel Advisors | 24,700 | $46,683 | 0.00% |